Stock Code
688488.SH
EN / CN
Aidea Milestones
Aidea Milestones
Home  >  News Center  > 

Aidea Milestones

2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
  • January
    Class 2 new drug Dolutegravir, Lamivudine and Tenofovir Tablets (ADC205) received clinical trial approval
    Class 2 new drug Dolutegravir, Lamivudine and Tenofovir Tablets (ADC205) received clinical trial approval
    March
    Dolutegravir Sodium Tablets were approved for marketing
    Dolutegravir Sodium Tablets were approved for marketing
    April
    Long-acting PrEP drug ACC085 injection received clinical trial approval
    Long-acting PrEP drug ACC085 injection received clinical trial approval
    2026
  • 7月
    NDA for Aitribond ®was approved by the Zanzibar Food and Drug Agency (ZFDA)
    NDA for Aitribond<sup>®</sup>was approved by the Zanzibar Food and Drug Agency (ZFDA)
    March
    Human-derived protein product AD108 injection received clinical trial approval
    Human-derived protein product AD108 injection received clinical trial approval
    July
    The Company changed its name to "Jiangsu Aidea Pharmaceutical Group Co., Ltd."
    The Company changed its name to
    October
    Novel integrase inhibitor ACC017 officially initiated Phase III clinical trials
    Novel integrase inhibitor ACC017 officially initiated Phase III clinical trials
    October
    Human-derived protein product ADB116 for Injection received clinical trial approval
    Human-derived protein product ADB116 for Injection received clinical trial approval
    October
    Dr. Fu Heliang presented Phase II clinical results of Asuptegravir at the 10th Pharmaceutical Innovation and Investment Conference
    Dr. Fu Heliang presented Phase II clinical results of Asuptegravir at the 10th Pharmaceutical Innovation and Investment Conference
    October
    Class 1 new drug ADC118 Tablets in the HIV field received clinical trial approval
    Class 1 new drug ADC118 Tablets in the HIV field received clinical trial approval
    December
    Participated in 2 projects under the "Emerging and Major Infectious Disease Prevention and Control" National Science and Technology Major Project
    Participated in 2 projects under the
    2025
  • January
    Wholly-owned subsidiary "Chengdu Aidea" officially commenced operations
    Wholly-owned subsidiary
    February
    The Company was awarded "2023 Advanced Enterprise in Work Safety"
    The Company was awarded
    February
    The Company was re-certified as a "High-Tech Enterprise"
    The Company was re-certified as a
    February
    The Company was awarded "2023 Yangzhou Private Enterprise Innovation Top 20"
    The Company was awarded
    June
    The Company was selected in the "2023 China Small Molecule Drug Enterprise Innovation Power TOP 30"
    The Company was selected in the
    June
    Acquired controlling stake in Nanda Pharmaceutical, achieving integrated "human-derived protein API-to-drug product"
    Acquired controlling stake in Nanda Pharmaceutical, achieving integrated
    June
    NDA for Ainuovirine drug substance was approved and commercial production commenced
    NDA for Ainuovirine drug substance was approved and commercial production commenced
    July
    Two of the Company's anti-HIV innovative drugs were included in the Chinese Guidelines for the Diagnosis and Treatment of HIV/AIDS (2024 Edition)
    Two of the Company's anti-HIV innovative drugs were included in the Chinese Guidelines for the Diagnosis and Treatment of HIV/AIDS (2024 Edition)
    September
    Selected as a National-level Specialized, Sophisticated, Distinctive, and Innovative "Little Giant" Enterprise
    Selected as a National-level Specialized, Sophisticated, Distinctive, and Innovative
    October
    Supplemental new drug application for a new indication of Aitribond Tablets was approved
    Supplemental new drug application for a new indication of Aitribond Tablets was approved
    November
    Received the 2023 Jiangsu Provincial Science and Technology Award (Second Class)
    Received the 2023 Jiangsu Provincial Science and Technology Award (Second Class)
    2024
  • June
    The Company was selected in the "2022 China Small Molecule Drug Enterprise Innovation Power TOP 30"
    The Company was selected in the
    July
    The Company was named "Most Investable Enterprise of the Year" at the 3rd Jiangsu Capital Market Summit
    The Company was named
    September
    Jointly established the China AIDS Prevention and Treatment Innovative Drug Research Demonstration Base
    Jointly established the China AIDS Prevention and Treatment Innovative Drug Research Demonstration Base
    December
    Aitribond ®( (Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets) was included in the National Medical Insurance List, and Aibangde® (Ainuovirine Tablets) successfully renewed its inclusion
    Aitribond<sup>®</sup>( (Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets) was included in the National Medical Insurance List, and Aibangde® (Ainuovirine Tablets) successfully renewed its inclusion
    2023
  • April
    Collaborated with the Chinese Association of STD and AIDS Prevention and Control to launch the "Ai Yan" project
    Collaborated with the Chinese Association of STD and AIDS Prevention and Control to launch the
    December
    Aitribond ® (Ainuomiti Tablets) was approved for marketing
    Aitribond<sup>®</sup> (Ainuomiti Tablets) was approved for marketing
    2022
  • May
    The Company was awarded the title of "2019–2020 Yangzhou Civilized Enterprise"
    The Company was awarded the title of
    June
    Aibangde ® (Ainuovirine Tablets/ACC007 Tablets) was approved for marketing
    Aibangde<sup>®</sup> (Ainuovirine Tablets/ACC007 Tablets) was approved for marketing
    November
    Aidea Pharma's API—Ulinastatin—was awarded the title of "Jiangsu Provincial Specialized and Sophisticated Product"
    Aidea Pharma's API—Ulinastatin—was awarded the title of
    December
    Aibangde ®(Ainuovirine Tablets/ACC007 Tablets) was included in the National Medical Insurance List
    Aibangde<sup>®</sup>(Ainuovirine Tablets/ACC007 Tablets) was included in the National Medical Insurance List
    2021
  • July
    The Company was successfully listed on the STAR Market of the Shanghai Stock Exchange (Stock Abbreviation: Aidea, Stock Code: 688488)
    The Company was successfully listed on the STAR Market of the Shanghai Stock Exchange (Stock Abbreviation: Aidea, Stock Code: 688488)
    July
    ACC007 receives notification of acceptance for drug registration application
    ACC007 receives notification of acceptance for drug registration application
    2020
  • 2019
    Ulinastatin for Injection received clinical trial approval
    Ulinastatin for Injection received clinical trial approval
    2019
    The Company completed shareholding reform and changed its name to "Jiangsu Aidea Pharmaceutical Co., Ltd."
    The Company completed shareholding reform and changed its name to
    2019
    ACC008 was included in the "National New Drug Innovation" Major Project of China under the 13th Five-Year Plan
    ACC008 was included in the
    2019
    ACC010 received clinical trial approval
    ACC010 received clinical trial approval
    2019
    Nanjing Accelas Pharmaceutical Co., Ltd. was recognized as the "Nanjing Municipal Antiviral Drug R&D Engineering Technology Research Center"
    Nanjing Accelas Pharmaceutical Co., Ltd. was recognized as the
    2019
  • 2018
    ACC007 Tablets (ACC008) received clinical trial approval
    ACC007 Tablets (ACC008) received clinical trial approval
    2018
    The Company obtained the GMP Certificate for Pharmaceutical Products
    The Company obtained the GMP Certificate for Pharmaceutical Products
    2018
    ACC007 received the 2018 Provincial Enterprise Innovation and Achievement Transformation Special Fund
    ACC007 received the 2018 Provincial Enterprise Innovation and Achievement Transformation Special Fund
    2018
  • 2017
    The anti-HIV Class 1 new drug ACC007 was included in the "National New Drug Innovation" Major Project of China under the 13th Five-Year Plan
    The anti-HIV Class 1 new drug ACC007 was included in the
    2017
    The anti-HIV Class 1 new drug ACC007 received clinical trial approval
    The anti-HIV Class 1 new drug ACC007 received clinical trial approval
    2017
    The Company established a Jiangsu Provincial Postgraduate Workstation
    The Company established a Jiangsu Provincial Postgraduate Workstation
    2017
  • 2016
    The Company changed its name to "Jiangsu Aidea Pharmaceutical Co., Ltd."
    The Company changed its name to
    2016
  • 2015
    The Company was recognized as a "Jiangsu Provincial Enterprise Technology Center"
    The Company was recognized as a
    2015
    Introduced strategic investments from Jiangsu Govtor Capital Group Co., Ltd., Huatai Securities Co., Ltd., and STARR
    Introduced strategic investments from Jiangsu Govtor Capital Group Co., Ltd., Huatai Securities Co., Ltd., and STARR
    2015
    Acquired Yangzhou Xingdou Pharmaceutical Co., Ltd. (later renamed "Yangzhou Aidea Pharmaceutical Co., Ltd.)
    Acquired Yangzhou Xingdou Pharmaceutical Co., Ltd. (later renamed
    2015
  • 2014
    Completed shareholding reform and initiated Series A financingEntered the HIV innovative drug R&D field
    Completed shareholding reform and initiated Series A financingEntered the HIV innovative drug R&D field
    2014
    Human Urinary Kallidinogenase Crude Product was recognized as a "Jiangsu Provincial High-Tech Product" for 2014
    Human Urinary Kallidinogenase Crude Product was recognized as a
    2014
    The Company was recognized as the "Jiangsu Provincial Engineering Technology Research Center for Human Urinary Protein
    The Company was recognized as the
    2014
    The Company established an Academician Workstation
    The Company established an Academician Workstation
    2014
  • November
    "R&D and Industrialization Project of Online Adsorption Technology for Active Proteins and Large-Scale Preparation of Ulinastatin and Albumin" received the 2013 Provincial Enterprise Innovation and Achievement Transformation Special Fund
    Jiangsu Aidea Pharmaceutical Group
    2013
    "R&D of Large-Scale Production of Ulinastatin Crude Product by Online Adsorption Method" won the First-Class Science and Technology Award
    Jiangsu Aidea Pharmaceutical Group
    2013
    Subsidiary Nanjing Accelas Pharmaceutical Co., Ltd. was established
    Subsidiary Nanjing Accelas Pharmaceutical Co., Ltd. was established
    2013
    Online Adsorption Urokinase API was recognized as a "Jiangsu Provincial High-Tech Product" for 2013
    Online Adsorption Urokinase API was recognized as a
    2013
    The Company was selected into Jiangsu Provincial Science and Technology Enterprise Listing Training Program
    The Company was selected into Jiangsu Provincial Science and Technology Enterprise Listing Training Program
    2013
  • 2012
    The Company was recognized as a "Yangzhou Municipal Enterprise Technology Center" for 2012
    The Company was recognized as a
    2012
    The Company was included in the 2012 Yangzhou Municipal Engineering Research Center Construction Project List
    The Company was included in the 2012 Yangzhou Municipal Engineering Research Center Construction Project List
    2012
    The Company received the Yangzhou Science and Technology Progress Award (First Class)
    The Company received the Yangzhou Science and Technology Progress Award (First Class)
    2012
    Ulinastatin API with Low Vasoactive Substance Content was recognized as a "Jiangsu Provincial High-Tech Product" for 2012
    Ulinastatin API with Low Vasoactive Substance Content was recognized as a
    2012
  • 2011
    Human Urine-Derived Albumin API was recognized as a "Jiangsu Provincial High-Tech Product" for 2011
    Human Urine-Derived Albumin API was recognized as a
    2011
    The Company was awarded the title of "High-Tech Enterprise"
    The Company was awarded the title of
    2011
  • 2010
    Ulinastatin API was recognized as a "Jiangsu Provincial High-Tech Product" for 2010
    Ulinastatin API was recognized as a
    2010
  • 2009
    Yangzhou Aidea Biotech Co., Ltd. was established (predecessor of Aidea Pharma)
    Yangzhou Aidea Biotech Co., Ltd. was established (predecessor of Aidea Pharma)
    2009